US Stock Market Move | ZAI LAB (ZLAB.US) rose more than 5%, and Zoci is expected to become its first globally listed product in the oncology field.

On Wednesday, ZAI LAB (ZLAB.US) rose more than 5%, closing at $19.72. In terms of news, on January 13, ZAI LAB introduced its 2026 strategic focus and clinical development progress at the 44th J.P. Morgan Healthcare Conference. Zocilurtatug pelitecan (Zoci) is expected to become the company's first globally marketed product in the field of oncology. The company plans to initiate three key registration studies by the end of 2026, including second-line and above small cell lung cancer, first-line small cell lung cancer, and neuroendocrine cancer.